Shares of Perrigo Company plc (NYSE:PRGO – Get Free Report) fell 4.4% during trading on Wednesday . The company traded as low as $12.29 and last traded at $12.2830. 110,652 shares were traded during trading, a decline of 97% from the average session volume of 3,182,696 shares. The stock had previously closed at $12.85.
Analyst Ratings Changes
Several research analysts recently issued reports on PRGO shares. Zacks Research upgraded shares of Perrigo from a “strong sell” rating to a “hold” rating in a research note on Monday, April 27th. Weiss Ratings upgraded shares of Perrigo from a “sell (d-)” rating to a “sell (d)” rating in a report on Thursday, August 6th. Finally, Wall Street Zen upgraded Perrigo from a “hold” rating to a “buy” rating in a research note on Saturday. One research analyst has rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Hold” and an average target price of $19.33.
Get Our Latest Analysis on Perrigo
Perrigo Price Performance
Perrigo (NYSE:PRGO – Get Free Report) last posted its quarterly earnings results on Wednesday, August 5th. The company reported $0.50 EPS for the quarter, beating analysts’ consensus estimates of $0.39 by $0.11. The firm had revenue of $1.02 billion for the quarter, compared to analysts’ expectations of $1.02 billion. Perrigo had a negative net margin of 41.85% and a positive return on equity of 11.25%. The business’s revenue for the quarter was down 3.1% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.06) earnings per share. Perrigo has set its FY 2026 guidance at 2.250-2.550 EPS. On average, research analysts forecast that Perrigo Company plc will post 2.2 earnings per share for the current fiscal year.
Perrigo Dividend Announcement
The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 15th. Shareholders of record on Friday, August 28th will be issued a dividend of $0.29 per share. This represents a $1.16 dividend on an annualized basis and a yield of 9.4%. The ex-dividend date of this dividend is Friday, August 28th. Perrigo’s dividend payout ratio is currently -9.27%.
Institutional Investors Weigh In On Perrigo
A number of hedge funds have recently modified their holdings of PRGO. EverSource Wealth Advisors LLC lifted its position in Perrigo by 116.0% during the fourth quarter. EverSource Wealth Advisors LLC now owns 1,888 shares of the company’s stock valued at $26,000 after purchasing an additional 1,014 shares in the last quarter. Geneos Wealth Management Inc. raised its stake in shares of Perrigo by 439.1% in the first quarter. Geneos Wealth Management Inc. now owns 965 shares of the company’s stock worth $27,000 after buying an additional 786 shares during the period. UMB Bank n.a. lifted its position in shares of Perrigo by 161.5% during the 4th quarter. UMB Bank n.a. now owns 1,964 shares of the company’s stock valued at $27,000 after buying an additional 1,213 shares in the last quarter. Meeder Asset Management Inc. purchased a new stake in Perrigo in the 4th quarter worth approximately $28,000. Finally, CWM LLC raised its stake in Perrigo by 230.0% during the 4th quarter. CWM LLC now owns 2,191 shares of the company’s stock worth $31,000 after acquiring an additional 1,527 shares during the period. Institutional investors own 95.91% of the company’s stock.
About Perrigo
Perrigo Company plc is a global healthcare supplier specializing in over-the-counter (OTC) and self-care products, as well as generic prescription pharmaceuticals and active pharmaceutical ingredients. The company develops, manufactures and distributes a broad array of consumer health products, including analgesics, vitamins and supplements, digestive health remedies, topical treatments, and infant formulas. Perrigo’s focus on private-label solutions has made it a leading partner for retailers and pharmacy chains seeking high-quality, value-oriented alternatives to branded medications and health supplements.
Organized across three principal business segments—Consumer Healthcare, Prescription Pharmaceuticals and Active Pharmaceutical Ingredients—Perrigo’s operations span research and development, manufacturing, quality assurance and global distribution.
Featured Articles
- Five stocks we like better than Perrigo
- Intel’s Rally Gave It a $20 Billion Opportunity and Now Comes the Hard Part
- Visa’s AI Opportunity Is Hiding in Every Transaction
- On Holding’s Price Stumble May Be an Opening for a Company Built to Run
- TSMC’s 44.7% Sales Surge Signals the AI Boom Is Still Alive
Receive News & Ratings for Perrigo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Perrigo and related companies with MarketBeat.com's FREE daily email newsletter.
